Local anesthetic use in tumescent liposuction: an American Society of Plastic Surgeons survey.
Abstract
[BACKGROUND] Current guidelines favor the use of lidocaine in liposuction wetting solutions. The use of bupivacaine as an alternative remains controversial despite reports of its use with safe and favorable outcomes suggesting faster postoperative recovery time secondary to improved pain control. The goals of this study were to determine the prevalence of bupivacaine use, examine liposuction practices of bupivacaine users, and elucidate opinions regarding bupivacaine use.
[METHODS] An online survey was distributed to 2500 randomly selected members of the American Society of Plastic Surgeons. Data were collected and analyzed with special attention toward the practice and opinions of bupivacaine use.
[RESULTS] The response rate of the survey met the average American Society of Plastic Surgeons online survey response rate at 12.8% (n=320). Respondents (7.2%; n=22) reported using bupivacaine in their wetting solutions (bupivacaine group) and provided a dosage range of 62.5 to 150 mg. Respondents (83.5%; n=254) reported using either lidocaine or prilocaine (no-bupivacaine group). There were no reports of bupivacaine toxicity in 2011. The demographic profile and liposuction practices of both groups were comparable. Although 36% of the no-bupivacaine group did not know or had no opinion on when it is appropriate to use bupivacaine in liposuction wetting solutions, 85% of this group has used bupivacaine for other clinical purposes.
[CONCLUSIONS] A review of 320 plastic surgeons' experiences revealed that 7% of respondents are using bupivacaine in their tumescent solutions with no reported cases of toxicity. Bupivacaine users differed dramatically only in their opinion regarding the safety of bupivacaine in tumescent liposuction. The recent studies suggesting better postoperative pain control with bupivacaine along with the proportion of respondents reporting bupivacaine use call for distinct guidelines on bupivacaine use in liposuction. Further studies, including a rigorous clinical trial documenting the safety and efficacy of bupivacaine when compared with lidocaine, would be warranted.
[METHODS] An online survey was distributed to 2500 randomly selected members of the American Society of Plastic Surgeons. Data were collected and analyzed with special attention toward the practice and opinions of bupivacaine use.
[RESULTS] The response rate of the survey met the average American Society of Plastic Surgeons online survey response rate at 12.8% (n=320). Respondents (7.2%; n=22) reported using bupivacaine in their wetting solutions (bupivacaine group) and provided a dosage range of 62.5 to 150 mg. Respondents (83.5%; n=254) reported using either lidocaine or prilocaine (no-bupivacaine group). There were no reports of bupivacaine toxicity in 2011. The demographic profile and liposuction practices of both groups were comparable. Although 36% of the no-bupivacaine group did not know or had no opinion on when it is appropriate to use bupivacaine in liposuction wetting solutions, 85% of this group has used bupivacaine for other clinical purposes.
[CONCLUSIONS] A review of 320 plastic surgeons' experiences revealed that 7% of respondents are using bupivacaine in their tumescent solutions with no reported cases of toxicity. Bupivacaine users differed dramatically only in their opinion regarding the safety of bupivacaine in tumescent liposuction. The recent studies suggesting better postoperative pain control with bupivacaine along with the proportion of respondents reporting bupivacaine use call for distinct guidelines on bupivacaine use in liposuction. Further studies, including a rigorous clinical trial documenting the safety and efficacy of bupivacaine when compared with lidocaine, would be warranted.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | liposuction
|
지방흡입 | dict | 7 | |
| 약물 | lidocaine
|
리도카인 | dict | 3 | |
| 약물 | bupivacaine
|
C0006400
bupivacaine
|
scispacy | 1 | |
| 약물 | prilocaine
|
C0033124
prilocaine
|
scispacy | 1 | |
| 약물 | no-bupivacaine
|
scispacy | 1 | ||
| 약물 | bupivacaine toxicity
|
scispacy | 1 | ||
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] A
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | toxicity
|
C0040539
Toxicity aspects
|
scispacy | 1 | |
| 질환 | n=320
|
scispacy | 1 |
MeSH Terms
Anesthetics, Local; Attitude of Health Personnel; Bupivacaine; Data Collection; Humans; Lidocaine; Lipectomy; Practice Patterns, Physicians'; Surgery, Plastic; United States
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative effects of pharmacological interventions in the prophylactic treatment of tension-type headache: systematic review and network meta-analysis.
- Clinical safety of a low-modification hyaluronic acid filler (MoD 2%) for facial rejuvenation.
- Quantitative Assessment of Cannula Kinematics in Liposuction Surgical Procedures Using a Marker-Based Tracking System.
- Fat harvesting protocol for enhanced stem cell viability - pilot study.